The ERS/EAACI statement on severe exacerbations of asthma, and how to deal with non-allergic severe asthma

M. Gaga (Athens, Greece)

Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma
Session: Pathophysiology and clinical insights into severe non-allergic asthma
Session type: Symposium
Number: 4907
Disease area: Airway diseases

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Gaga (Athens, Greece). The ERS/EAACI statement on severe exacerbations of asthma, and how to deal with non-allergic severe asthma. International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Difficult to treat asthma
Source: Annual Congress 2006 - Clinical year in review
Year: 2006


Only severe asthma?
Source: International Congress 2019 – PG11 Severe paediatric asthma
Year: 2019


Immunotherapy in severe asthma
Source: ERS webinar 2021: Immunotherapy in severe asthma
Year: 2021


Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017

Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma
Source: Eur Respir J 2002; 19: 846-852
Year: 2002



Difficult-to-treat and severe asthma
Source: Breathe 2014; 10: 91-94
Year: 2014

Omalizumab in children with severe persistent allergic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010

Management of difficult-to-treat severe asthma
Source: Eur Respir Mon 2011; 51: 282-296
Year: 2011


Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017


Difficult-to-treat asthma: how serious is the problem and what are the issues?
Source: Eur Respir Mon 2011; 51: 1-15
Year: 2011


Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009

Asthma exacerbations in relation to severe asthma
Source: Eur Respir Mon 2011; 51: 120-129
Year: 2011


Evolution from mild to severe asthma; the severe asthma clinic perspective
Source: International Congress 2019 – Clinical implications of asthma management
Year: 2019


Refining asthma treatment for mild asthma
Source: Virtual Congress 2020 – Rethinking asthma
Year: 2020


Pathophysiology of severe non-allergic asthma
Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma
Year: 2019


The management of mild asthma
Source: Eur Respir J, 57 (4) 2003051; 10.1183/13993003.03051-2020
Year: 2021



Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015

The association between asthma, chronic bronchitis/emphysema and rhinitis
Source: Eur Respir J 2001; 18: Suppl. 33, 201s
Year: 2001